Atropine-neostigmine mixture: a dose-response study.
The dose-response relationship and the doses of atropine required to prevent neostigmine from lowering heart rates below baseline in 50 per cent (ED50) and 95 percent (ED95) of patients after antagonism of pancuronium-induced neuromuscular blockade were determined in 70 patients with neostigmine-atropine mixtures. Neostigmine 0.04 mg.kg-1 (group A, n = 35) or 0.06 mg.kg-1 (group B, n = 35) was randomly mixed with one of seven doses of atropine (ranging from 0.014 to 0.04 mg.kg-1) in group A and from 0.02 to 0.04 mg.kg-1 in group B), with dose-response curves for atropine being constructed for both groups 5 and 10 min after injection of the mixture. These dose-response curves were found to be parallel in both groups. The calculated ED50 and ED95 values of atropine were similar in both groups. The estimated ED50 doses of atropine in groups A and B at 5 min were 0.031 and 0.033 mg.kg-1 respectively, and at 10 min the ED50 doses were 0.037 and 0.037 mg.kg-1 respectively. The calculated ED95 doses of atropine in groups A and B at 5 min were 0.05 and 0.046 mg.kg-1, and at 10 min the ED95 doses were also similar, being 0.06 and 0.055 mg.kg-1 respectively. Under the conditions employed in this study it would seem that in order to prevent late reductions in heart rates, the appropriate doses of atropine when used with neostigmine should be greater than that commonly used.
Department of Anaesthesiology, King Saud University, King Khalid University Hospital, Riyadh, Saudi Arabia.
M
M
Naguib
M
M
Gomaa
D000328:Adult; D000769:Anesthesia, Inhalation; D001285:Atropine / Q000008:administration & dosage / Q000494:pharmacology*; D001919:Bradycardia / Q000139:chemically induced / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D009388:Neostigmine / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D009469:Neuromuscular Junction / Q000187:drug effects*; D010197:Pancuronium / Q000037:antagonists & inhibitors*
D009388:Neostigmine; D001285:Atropine; D010197:Pancuronium